Your healthcare provider will help select between GLP-1 or GLP-1/GIP and a complementary additive, such as B12, L-carnitine, or glycine, based on what aligns best with your wellness goals
Patients were also required to have at least one outpatient encounter within the four years prior the prescription
For instance, GLP-1RAs were demonstrated to reduce the risk of cardiovascular events (5) by decreasing the blood pressure (6), improving microvascular function, and reducing inflammation (7)
Drug interactions and metabolism Weight loss associated with GLP-1R use may alter drug metabolism of weight-based medications (e.g., levothyroxine, warfarin )
P., Hathaway, D
FDA Approval Timeline As of mid-2025, Retatrutide is: Still under investigation in phase 3 clinical trials Expected to complete primary trials by late 2025 Anticipated to receive FDA approval in 2026 Until then, it is available only for research purposes , and should not be used outside of controlled clinical settings without professional supervision